List view / Grid view
Molecular Devices announced the launch of the new SoftMax® Pro 7.1 GxP Software with complete validation tools which achieves full FDA 21 CFR Part 11 compliance in GMP/GLP labs...
6 November 2018 | By PerkinElmer
This webinar outlined the fundamentals of a design process where an experimental analytics data workflow is being integrated into a more seamlessly interactive platform...
25 October 2018 | By NanoTemper Technologies
In this webinar, speakers presented results of integrated fragment-based approaches that have led to the discovery of the first ligands of IDO1 that are able to modulate non-catalytic signalling functions of the enzyme...
Targeting the fibrin protein could ensure that fibrin leaking through the blood-brain barrier does not cause inflammation or disease in the brain...
A comprehensive study reveals an expanding universe of 'darkest of the dark matter' RNAs in dopamine-producing cells in our brains...
Researchers have reported finding on an epigenetic signature in patient cells that appears to predict inflammation risk in Crohn's disease...
Mitochondrial dysfunction has been widely implicated in the neuronal degeneration in Parkinson’s disease (PD). Mitochondria-targeted protective compounds that prevent or minimise a wide range of mitochondrial defects constitute potential therapeutic strategies in the prevention and treatment of neuronal degeneration in PD.
Synthetic biology is broadly defined as the design and construction of novel artificial biological pathways, organisms or devices; or the redesign of existing natural biological systems.1 It brings together a range of disciplines and skills, from biology and chemistry to computing, bioinformatics and engineering.
This webinar, held on 28 June 2018, illustrated the optimisation of hits derived from a target-agnostic phenotypic screen, using a strategy based on combining bioactivity profiling and reference compound characterisation. Keynote speaker Arsenio Nueda, Head of Molecular Biology at Almirall, responded as follows to questions posed during the webinar.
14 August 2018 | By Bio-Techne
With recent advances in medicine, cellular therapies are one step closer to becoming a reality where re-programmed cells, tissues and organs can be used as therapeutic agents. This webinar discussed the journey of medical treatments from small molecule to cellular therapies...
A modified form of botulinum toxin gives long-lasting pain relief in mice without adverse effects...
Researchers identify Parkinson's disease as a possible autoimmune disease...
New research on how cannabis use alters eating behaviour could lead to treatments for appetite loss in chronic illness...
Vascular Endothelial Growth Factor C (VEGF-C) could aid the repair and recovery of hearts after a heart attack, by enabling immune cells to clear dead and dying cells...
